Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
11.12
+0.32 (2.96%)
At close: Jun 8, 2026, 4:00 PM EDT
11.00
-0.12 (-1.08%)
After-hours: Jun 8, 2026, 7:58 PM EDT
Biohaven Earnings Call Transcripts
Fiscal Year 2024
-
Troriluzole demonstrated a 50%-70% reduction in SCA progression over three years, with significant delays in disease decline and reduced fall risk, meeting all primary and secondary endpoints. The therapy was safe, well-tolerated, and is poised for FDA and EMA submissions, potentially becoming the first approved treatment for SCA.